Nathan Rimmke — Rochester Hills, Michigan

Nathan Rimmke is a clinical research site located in Rochester Hills, Michigan, United States 48307.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Nathan Rimmke has participated in 1 clinical trials.

Therapeutic areas: Degenerative Osteoarthritis.

Sponsors: Kolon TissueGene, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Rochester Hills

Browse all research sites in Michigan · View every site in Rochester Hills

• Ascension Medical Group - University Orthopaedic Specialists
• Ascension Providence Rochester Hospital
• Oakland University
• Crittenton Hospital Medical Center
• Henry Ford Rochester Hospital
• Wayne State University Family Medicine Clinic
• Great Lakes Cancer Management Specialists-Rochester Hills
• Rochester Center for Behavioral Medicine
• Research Site
• Rochester Medical Group
• Michigan Orthopaedic Spine Surgeons
• Advanced Cardiology Associates

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Nathan Rimmke?

Nathan Rimmke has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Nathan Rimmke conducted?

Nathan Rimmke has 1 clinical trials on record. Their work covers Degenerative Osteoarthritis.

Is Nathan Rimmke accredited by Crixeo Clinical Trials?

Nathan Rimmke has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Nathan Rimmke?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.